Glioblastoma stem cell metabolism and immunity

1.

Alvarado, A. G., Thiagarajan, P. S., Mulkearns-Hubert, E. E., Silver, D. J., Hale, J. S., Alban, T. J., … Lathia, J. D. (2017). Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell, 20(4), 450–461.e4. https://doi.org/10.1016/j.stem.2016.12.001

2.

Garnier, D., Renoult, O., Alves-Guerra, M.-C., Paris, F., & Pecqueur, C. (2019). Glioblastoma stem-like cells, metabolic strategy to kill a challenging target. Frontiers in Oncology, 9, 118. https://doi.org/10.3389/fonc.2019.00118CrossRefPubMedPubMedCentral

3.

Esparza, R., Azad, T. D., Feroze, A. H., Mitra, S. S., & Cheshier, S. H. (2015). Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-Oncology, 123(3), 449–457. https://doi.org/10.1007/s11060-015-1729-xCrossRefPubMed

4.

Geller, M. A., & Miller, J. S. (2011). Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 3(12), 1445–1459. https://doi.org/10.2217/imt.11.131CrossRefPubMed

5.

National Cancer Institute. (n.d.). Surveillance, Epidemiology, and End Results (SEER) Program Explorer Application. Retrieved April 5, 2023, from https://seer.cancer.gov/statistics-network/explorer/application.html?site=661&data_type=5&graph_type=12&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&series=9&race=1&age_range=15&prev_duration=1&advopt_precision=1&hdn_view=1

6.

Lam, S., Lin, Y., Zinn, P., Su, J., & Pan, I.-W. (2018). Patient and treatment factors associated with survival among pediatric glioblastoma patients: A Surveillance, Epidemiology, and End Results study. Journal of Clinical Neuroscience, 47, 285–293. https://doi.org/10.1016/j.jocn.2017.10.041CrossRefPubMed

7.

Da, W., Xueli, C., Xiao, P., & Yian, X. (2020). Prognostic factors and survival prediction of pediatric glioblastomas: A population-based study. Turkish Neurosurgeryhttps://doi.org/10.5137/1019-5149.JTN.31915-20.2

8.

Hardell, L., Carlberg, M., & Mild, K. H. (2006). Case-control study of the association between the use of cellular and cordless telephones and malignant brain tumors diagnosed during 2000–2003. Environmental Research, 100(2), 232–241. https://doi.org/10.1016/j.envres.2005.04.006CrossRefPubMed

9.

INTERPHONE Study Group. (2010). Brain tumour risk in relation to mobile telephone use: Results of the INTERPHONE international case-control study. International Journal of Epidemiology, 39(3), 675–694. https://doi.org/10.1093/ije/dyq079CrossRef

10.

Lahkola, A., Auvinen, A., Raitanen, J., Schoemaker, M. J., Christensen, H. C., Feychting, M., … Salminen, T. (2007). Mobile phone use and risk of glioma in 5 North European countries. International Journal of Cancer, 120(8), 1769–1775. https://doi.org/10.1002/ijc.22503

11.

World Health Organisation. (2011, May 31). IARC classifies radiofrequency electromagnetic fields as possibly carcinogenic to humans. Retrieved July 5, 2023, from https://www.iarc.who.int/pressrelease/iarc-classifies-radiofrequency-electromagnetic-fields-as-possibly-carcinogenic-to-humans/

12.

Deltour, I., Poulsen, A. H., Johansen, C., Feychting, M., Johannesen, T. B., Auvinen, A., & Schüz, J. (2022). Time trends in mobile phone use and glioma incidence among males in the Nordic Countries, 1979–2016. Environment International, 168, 107487. https://doi.org/10.1016/j.envint.2022.107487CrossRefPubMedPubMedCentral

13.

Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2016). Pediatric gliomas as neurodevelopmental disorders. Glia, 64(6), 879–895. https://doi.org/10.1002/glia.22945CrossRefPubMed

14.

Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., … Pfister, S. M. (2012). Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell, 22(4), 425–437. https://doi.org/10.1016/j.ccr.2012.08.024

15.

Janke, R., Iavarone, A. T., & Rine, J. (2017). Oncometabolite D-2-hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases. eLife, 6. https://doi.org/10.7554/eLife.22451

16.

Zong, H., Parada, L. F., & Baker, S. J. (2015). Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harbor Perspectives in Biology, 7(5), a020610. https://doi.org/10.1101/cshperspect.a020610CrossRefPubMedPubMedCentral

17.

Jones, C., & Baker, S. J. (2014). Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nature Reviews. Cancer, 14(10). https://doi.org/10.1038/nrc3811

18.

Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-Oncology, 23(12 Suppl 2), iii1–iii105. https://doi.org/10.1093/neuonc/noab200

19.

Rowitch, D. H., & Kriegstein, A. R. (2010). Developmental genetics of vertebrate glial-cell specification. Nature, 468(7321), 214–222. https://doi.org/10.1038/nature09611CrossRefPubMed

20.

Takebayashi, H., & Ikenaka, K. (2015). Oligodendrocyte generation during mouse development. Glia, 63(8), 1350–1356. https://doi.org/10.1002/glia.22863CrossRefPubMed

21.

Yacob, M. S., & Johnston, D. L. (2016). Glioblastoma multiforme: A pediatric case series. Journal of Case Reports and Images in Oncology, 2, 18–22. https://doi.org/10.5348/Z10-2016-14-CS-5CrossRef

22.

Wilne, S., Collier, J., Kennedy, C., Koller, K., Grundy, R., & Walker, D. (2007). Presentation of childhood CNS tumours: A systematic review and meta-analysis. The Lancet Oncology, 8(8), 685–695. https://doi.org/10.1016/S1470-2045(07)70207-3CrossRefPubMed

23.

Das, K. K., Mehrotra, A., Nair, A. P., Kumar, S., Srivastava, A. K., Sahu, R. N., & Kumar, R. (2012). Pediatric glioblastoma: Clinico-radiological profile and factors affecting the outcome. Child’s Nervous System, 28(12), 2055–2062. https://doi.org/10.1007/s00381-012-1890-xCrossRefPubMed

24.

McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021). Glioblastoma: Clinical presentation, diagnosis, and management. BMJ, 374, n1560. https://doi.org/10.1136/bmj.n1560CrossRefPubMed

25.

Ozawa, M., Brennan, P. M., Zienius, K., Kurian, K. M., Hollingworth, W., Weller, D., … Ben-Shlomo, Y. (2019). The usefulness of symptoms alone or combined for general practitioners in considering the diagnosis of a brain tumour: A case-control study using the clinical practice research database (CPRD) (2000–2014). BMJ Open, 9(8), e029686. https://doi.org/10.1136/bmjopen-2019-029686

26.

Ideguchi, M., Kajiwara, K., Goto, H., Sugimoto, K., Nomura, S., Ikeda, E., & Suzuki, M. (2015). MRI findings and pathological features in early-stage glioblastoma. Journal of Neuro-Oncology, 123(2), 289–297. https://doi.org/10.1007/s11060-015-1797-yCrossRefPubMed

27.

Verburg, N., Hoefnagels, F. W. A., Barkhof, F., Boellaard, R., Goldman, S., Guo, J., … De Witt Hamer, P. C. (2017). Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: A meta-analysis. AJNR: American Journal of Neuroradiology, 38(10), 1884–1891. https://doi.org/10.3174/ajnr.A5368

28.

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., … Chang, S. M. (2010). Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(11), 1963–1972. https://doi.org/10.1200/JCO.2009.26.3541

29.

van den Bent, M. J., Wefel, J. S., Schiff, D., Taphoorn, M. J. B., Jaeckle, K., Junck, L., … Jacobs, A. H. (2011). Response assessment in neuro-oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. The Lancet. Oncology, 12(6), 583–593. https://doi.org/10.1016/S1470-2045(11)70057-2

30.

Cohen, K. J., Heideman, R. L., Zhou, T., Holmes, E. J., Lavey, R. S., Bouffet, E., & Pollack, I. F. (2011). Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children’s Oncology Group. Neuro-Oncology, 13(4), 410–416. https://doi.org/10.1093/neuonc/noq205CrossRefPubMedPubMedCentral

31.

Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., … Heideman, R. L. (2011). Temozolomide in the treatment of high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-Oncology, 13(3), 317–323. https://doi.org/10.1093/neuonc/noq191

32.

Warren, K. E. (2012). Diffuse intrinsic pontine glioma: Poised for progress. Frontiers in Oncology, 2, 205. https://doi.org/10.3389/fonc.2012.00205CrossRefPubMedPubMedCentral

33.

Tallman, M. M., Zalenski, A. A., & Venere, M. (2021). Cancer stem cells in pediatric brain tumors. In W. Debinski (Ed.), Gliomas. Brisbane (AU): Exon Publications. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK570697/

34.

Rich, J. N., & Bao, S. (2007). Chemotherapy and cancer stem cells. Cell Stem Cell, 1(4), 353–355. https://doi.org/10.1016/j.stem.2007.09.011CrossRefPubMed

35.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews Cancer, 8(10), 755–768. https://doi.org/10.1038/nrc2499CrossRefPubMed

36.

Taylor, M. D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., … Gilbertson, R. J. (2005). Radial glia cells are candidate stem cells of ependymoma. Cancer Cell, 8(4), 323–335. https://doi.org/10.1016/j.ccr.2005.09.001

37.

Milde, T., Kleber, S., Korshunov, A., Witt, H., Hielscher, T., Koch, P., … Witt, O. (2011). A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 122(5), 637–650. https://doi.org/10.1007/s00401-011-0866-3

38.

Huang, G.-H., Xu, Q.-F., Cui, Y.-H., Li, N., Bian, X.-W., & Lv, S.-Q. (2016). Medulloblastoma stem cells: Promising targets in medulloblastoma therapy. Cancer Science, 107(5), 583–589. https://doi.org/10.1111/cas.12925CrossRefPubMedPubMedCentral

39.

Sun, Y., Xu, C., Pan, C., Chen, X., Geng, Y., Wu, Y., … Zhang, L. (2019). Diffuse intrinsic pontine gliomas exhibit cell biological and molecular signatures of fetal hindbrain-derived neural progenitor cells. Neuroscience Bulletin, 35(2), 216–224. https://doi.org/10.1007/s12264-018-00329-6

40.

Filbin, M. G., Tirosh, I., Hovestadt, V., Shaw, M. L., Escalante, L. E., Mathewson, N. D., … Suvà, M. L. (2018). Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 360(6386), 331–335. https://doi.org/10.1126/science.aao4750

41.

Friedman, G. K., Raborn, J., Kelly, V. M., Cassady, K. A., Markert, J. M., & Gillespie, G. Y. (2013). Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology, 3, 28. https://doi.org/10.3389/fonc.2013.00028CrossRefPubMedPubMedCentral

42.

Abou-Antoun, T. J., Hale, J. S., Lathia, J. D., & Dombrowski, S. M. (2017). Brain cancer stem cells in adults and children: Cell biology and therapeutic implications. Neurotherapeutics, 14(2), 372–384. https://doi.org/10.1007/s13311-017-0524-0CrossRefPubMedPubMedCentral

43.

Siminovitch, L., McCulloch, E. A., & Till, J. E. (1963). The distribution of colony-forming cells among spleen colonies. Retrieved from https://tspace.library.utoronto.ca/handle/1807/2778

44.

Bifari, F., Pacelli, L., & Krampera, M. (2010). Immunological properties of embryonic and adult stem cells. World Journal of Stem Cells, 2(3), 50–60. https://doi.org/10.4252/wjsc.v2.i3.50CrossRefPubMedPubMedCentral

45.

Lombard, A., Digregorio, M., Delcamp, C., Rogister, B., Piette, C., & Coppieters, N. (2021). The subventricular zone, a hideout for adult and pediatric high-grade glioma stem cells. Frontiers in Oncology, 10. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2020.614930

46.

Skoda, J., & Veselska, R. (2018). Cancer stem cells in sarcomas: Getting to the stemness core. Biochimica et Biophysica Acta (BBA) - General Subjects, 1862(10), 2134–2139. https://doi.org/10.1016/j.bbagen.2018.07.006

47.

Genadry, K. C., Pietrobono, S., Rota, R., & Linardic, C. M. (2018). Soft tissue sarcoma cancer stem cells: An overview. Frontiers in Oncology, 8. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2018.00475

48.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983–3988. https://doi.org/10.1073/pnas.0530291100CrossRef

49.

Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65(23), 10946–10951. https://doi.org/10.1158/0008-5472.CAN-05-2018CrossRefPubMed

50.

Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67(10), 4827–4833. https://doi.org/10.1158/0008-5472.CAN-06-3557CrossRefPubMed

51.

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445(7123), 111–115. https://doi.org/10.1038/nature05384CrossRefPubMed

52.

Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., … De Maria, R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death & Differentiation, 15(3), 504–514. https://doi.org/10.1038/sj.cdd.4402283

53.

Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed

54.

Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019). Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer. Genes & Development, 33(11–12), 591–609. https://doi.org/10.1101/gad.324301.119CrossRef

55.

Caretti, V., Bugiani, M., Freret, M., Schellen, P., Jansen, M., van Vuurden, D., … Monje, M. (2014). Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 128(4), 605–607. https://doi.org/10.1007/s00401-014-1307-x

56.

Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003). Cancerous stem cells can arise from pediatric brain tumors. Proceedings of the National Academy of Sciences, 100(25), 15178–15183. https://doi.org/10.1073/pnas.2036535100CrossRef

57.

Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Di Valentin, E., … Rogister, B. (2017). CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro-Oncology, 19(1), 66–77. https://doi.org/10.1093/neuonc/now136

58.

Valdés-Rives, S. A., Casique-Aguirre, D., Germán-Castelán, L., Velasco-Velázquez, M. A., & González-Arenas, A. (2017). Apoptotic signaling pathways in glioblastoma and therapeutic implications. BioMed Research International, 2017, 7403747. https://doi.org/10.1155/2017/7403747CrossRefPubMedPubMedCentral

59.

Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023). Natural killer cell-based immunotherapy against glioblastoma. International Journal of Molecular Sciences, 24(3), 2111. https://doi.org/10.3390/ijms24032111CrossRefPubMedPubMedCentral

60.

Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018). Harnessing the immune system in glioblastoma. British Journal of Cancer, 119(10), 1171–1181. https://doi.org/10.1038/s41416-018-0258-8CrossRefPubMedPubMedCentral

61.

Daubon, T., Hemadou, A., Romero Garmendia, I., & Saleh, M. (2020). Glioblastoma immune landscape and the potential of new immunotherapies. Frontiers in Immunology, 11, 585616. https://doi.org/10.3389/fimmu.2020.585616CrossRefPubMedPubMedCentral

62.

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., … McArdle, S. E. B. (2020). Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Frontiers in Immunology, 11, 582106. https://doi.org/10.3389/fimmu.2020.582106

63.

Gravina, G. L., Colapietro, A., Mancini, A., Rossetti, A., Martellucci, S., Ventura, L., … Festuccia, C. (2022). ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma. Cancers, 14(2), 289. https://doi.org/10.3390/cancers14020289

64.

Jiang, T., Wu, W., Zhang, H., Zhang, X., Zhang, D., Wang, Q., … Hang, C. (2017). High expression of B7-H6 in human glioma tissues promotes tumor progression. Oncotarget, 8(23), 37435–37447. https://doi.org/10.18632/oncotarget.16391

65.

Ravindranath, M. H., Filippone, E. J., Devarajan, A., & Asgharzadeh, S. (2019). Enhancing natural killer and CD8+ T cell-mediated anticancer cytotoxicity and proliferation of CD8+ T cells with HLA-E monospecific monoclonal antibodies. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 38(2), 38–59. https://doi.org/10.1089/mab.2018.0043CrossRefPubMedPubMedCentral

66.

Lupo, K. B., & Matosevic, S. (2020). CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. Journal of Hematology & Oncology, 13(1), 76. https://doi.org/10.1186/s13045-020-00913-2CrossRef

67.

Chitadze, G., & Kabelitz, D. (2022). Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches. Scandinavian Journal of Immunology, 96(2), e13201. https://doi.org/10.1111/sji.13201CrossRefPubMed

68.

Mitsutake, Y., Hiromatsu, Y., Saisho, M., Tokunaga, N., Ichikawa, Y., Kaji, M., & Irie, K. (1986). [Immunological assay of the CA-125 value in pleural effusion in various types of pleuritis--Its application as a differential diagnostic parameter of tuberculous or carcinomatous pleuritis]. Gan No Rinsho. Japan Journal of Cancer Clinics, 32(5), 453–457.

69.

Wiedemuth, R., Klink, B., Fujiwara, M., Schröck, E., Tatsuka, M., Schackert, G., & Temme, A. (2016). Janus face-like effects of Aurora B inhibition: Antitumoral mode of action versus induction of aneuploid progeny. Carcinogenesis, 37(10), 993–1003. https://doi.org/10.1093/carcin/bgw083CrossRefPubMed

70.

Barrow, A. D., Edeling, M. A., Trifonov, V., Luo, J., Goyal, P., Bohl, B., … Colonna, M. (2018). Natural killer cells control tumor growth by sensing a growth factor. Cell, 172(3), 534–548.e19. https://doi.org/10.1016/j.cell.2017.11.037

71.

Enderlin, M., Kleinmann, E. V., Struyf, S., Buracchi, C., Vecchi, A., Kinscherf, R., … Dinsart, C. (2009). TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Therapy, 16(2), 149–160. https://doi.org/10.1038/cgt.2008.62

72.

Zhong, J., Yang, X., Chen, J., He, K., Gao, X., Wu, X., … Zhang, N. (2022). Circular EZH2-encoded EZH2–92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. Nature Communications, 13(1), 4795. https://doi.org/10.1038/s41467-022-32311-2

73.

Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., … Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (New York, N.Y.), 295(5562), 2097–2100. https://doi.org/10.1126/science.1068440

74.

Kim, H., Kim, J., Sa, J. K., Ryu, B.-K., Park, K.-J., Kim, J., … Kang, S.-H. (2022). Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL/NK cell activation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 154, 113553. https://doi.org/10.1016/j.biopha.2022.113553

75.

Salazar, N., Carlson, J. C., Huang, K., Zheng, Y., Oderup, C., Gross, J., … Zabel, B. A. (2018). A chimeric antibody against ACKR3/CXCR7 in combination with TMZ activates immune responses and extends survival in mouse GBM models. Molecular Therapy: The Journal of the American Society of Gene Therapy, 26(5), 1354–1365. https://doi.org/10.1016/j.ymthe.2018.02.030

76.

Glumac, P. M., & LeBeau, A. M. (2018). The role of CD133 in cancer: A concise review. Clinical and Translational Medicine, 7(1), 18. https://doi.org/10.1186/s40169-018-0198-1CrossRefPubMedPubMedCentral

77.

Srivastava, S., Jackson, C., Kim, T., Choi, J., & Lim, M. (2019). A characterization of dendritic cells and their role in immunotherapy in glioblastoma: From preclinical studies to clinical trials. Cancers, 11(4), 537. https://doi.org/10.3390/cancers11040537CrossRefPubMedPubMedCentral

78.

Friedrich, M., Hahn, M., Michel, J., Sankowski, R., Kilian, M., Kehl, N., … Bunse, L. (2023). Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro-Oncology, 25(2), 263–276. https://doi.org/10.1093/neuonc/noac138

79.

Xu, L. W., Chow, K. K. H., Lim, M., & Li, G. (2014). Current vaccine trials in glioblastoma: A review. Journal of Immunology Research, 2014, 796856. https://doi.org/10.1155/2014/796856CrossRefPubMedPubMedCentral

80.

Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Van Ginderachter, J. A. (2020). Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife, 9, e52176. https://doi.org/10.7554/eLife.52176

81.

Wang, H., Zhou, H., Xu, J., Lu, Y., Ji, X., Yao, Y., … Wan, J. (2021). Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Letters, 496, 134–143. https://doi.org/10.1016/j.canlet.2020.09.028

82.

Tang, O. Y., Binder, Z. A., O’Rourke, D. M., & Bagley, S. J. (2023). Optimizing CAR-T therapy for glioblastoma. Molecular Diagnosis & Therapyhttps://doi.org/10.1007/s40291-023-00671-0

83.

Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021). Cancer immune evasion through loss of MHC class I antigen presentation. Frontiers in Immunology, 12, 636568. https://doi.org/10.3389/fimmu.2021.636568CrossRefPubMedPubMedCentral

84.

Nduom, E. K., Weller, M., & Heimberger, A. B. (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17 Suppl 7(Suppl 7), vii9–vii14. https://doi.org/10.1093/neuonc/nov151

85.

Silver, A., Feier, D., Ghosh, T., Rahman, M., Huang, J., Sarkisian, M. R., & Deleyrolle, L. P. (2022). Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. Frontiers in Oncology, 12, 1022716. https://doi.org/10.3389/fonc.2022.1022716CrossRefPubMedPubMedCentral

86.

van Hooren, L., Handgraaf, S. M., Kloosterman, D. J., Karimi, E., van Mil, L. W. H. G., Gassama, A. A., … Akkari, L. (2023). CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma. Nature Cancer, 4(5), 665–681. https://doi.org/10.1038/s43018-023-00547-6

87.

Yoshioka, S., Ikeda, T., Fukuchi, S., Kawai, Y., Ohta, K., Murakami, H., … Asai, A. (2022). Identification and characterization of a novel dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase. International journal of tryptophan research: IJTR, 15, 11786469221138456. https://doi.org/10.1177/11786469221138456

88.

Zhang, Y., Jin, T., Dou, Z., Wei, B., Zhang, B., & Sun, C. (2022). The dual role of the CD95 and CD95L signaling pathway in glioblastoma. Frontiers in Immunology, 13, 1029737. https://doi.org/10.3389/fimmu.2022.1029737CrossRefPubMedPubMedCentral

89.

Ross, J. L., Velazquez Vega, J., Plant, A., MacDonald, T. J., Becher, O. J., & Hambardzumyan, D. (2021). Tumour immune landscape of paediatric high-grade gliomas. Brain: A Journal of Neurology, 144(9), 2594–2609. https://doi.org/10.1093/brain/awab155

90.

Hwang, E. I., Sayour, E. J., Flores, C. T., Grant, G., Wechsler-Reya, R., Hoang-Minh, L. B., … Pollack, I. F. (2022). The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 3(1), 11–24. https://doi.org/10.1038/s43018-021-00319-0

91.

Griesinger, A. M., Birks, D. K., Donson, A. M., Amani, V., Hoffman, L. M., Waziri, A., … Foreman, N. K. (2013). Characterization of distinct immunophenotypes across pediatric brain tumor types. Journal of Immunology (Baltimore, Md.: 1950), 191(9), 4880–4888. https://doi.org/10.4049/jimmunol.1301966

92.

Robinson, M. H., Vasquez, J., Kaushal, A., MacDonald, T. J., Velázquez Vega, J. E., Schniederjan, M., & Dhodapkar, K. (2020). Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal for Immunotherapy of Cancer, 8(2), e001066. https://doi.org/10.1136/jitc-2020-001066CrossRefPubMedPubMedCentral

93.

Lieberman, N. A. P., DeGolier, K., Kovar, H. M., Davis, A., Hoglund, V., Stevens, J., … Crane, C. A. (2019). Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy. Neuro-Oncology, 21(1), 83–94. https://doi.org/10.1093/neuonc/noy145

94.

Lin, G. L., Nagaraja, S., Filbin, M. G., Suvà, M. L., Vogel, H., & Monje, M. (2018). Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathologica Communications, 6(1), 51. https://doi.org/10.1186/s40478-018-0553-xCrossRefPubMedPubMedCentral

95.

Lei, M. M. L., & Lee, T. K. W. (2021). Cancer stem cells: Emerging key players in immune evasion of cancers. Frontiers in Cell and Developmental Biology, 9, 692940. https://doi.org/10.3389/fcell.2021.692940CrossRefPubMedPubMedCentral

96.

Zhu, X., Chen, H.-H., Gao, C.-Y., Zhang, X.-X., Jiang, J.-X., Zhang, Y., … Chen, Z.-G. (2020). Energy metabolism in cancer stem cells. World Journal of Stem Cells, 12(6), 448–461. https://doi.org/10.4252/wjsc.v12.i6.448

97.

Peiris-Pagès, M., Martinez-Outschoorn, U. E., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2016). Cancer stem cell metabolism. Breast Cancer Research, 18(1), 55. https://doi.org/10.1186/s13058-016-0712-6CrossRefPubMedPubMedCentral

98.

Kaur, J., & Bhattacharyya, S. (2021). Cancer stem cells: Metabolic characterization for targeted cancer therapy. Frontiers in Oncology, 11. Retrieved from https://www.frontiersin.org/articles/https://doi.org/10.3389/fonc.2021.756888

99.

Yu, L., Ji, K.-Y., Zhang, J., Xu, Y., Ying, Y., Mai, T., … Xu, Y. (2019). Core pluripotency factors promote glycolysis of human embryonic stem cells by activating GLUT1 enhancer. Protein & Cell, 10(9), 668–680. https://doi.org/10.1007/s13238-019-0637-9

100.

Wang, Z.-H., Peng, W.-B., Zhang, P., Yang, X.-P., & Zhou, Q. (2021). Lactate in the tumour microenvironment: From immune modulation to therapy. eBioMedicine, 73. https://doi.org/10.1016/j.ebiom.2021.103627

101.

Lim, K. S., Lim, K. J., Price, A. C., Orr, B. A., Eberhart, C. G., & Bar, E. E. (2014). Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene, 33(35), 4433–4441. https://doi.org/10.1038/onc.2013.390CrossRefPubMed

102.

Goidts, V., Bageritz, J., Puccio, L., Nakata, S., Zapatka, M., Barbus, S., … Radlwimmer, B. (2012). RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene, 31(27), 3235–3243. https://doi.org/10.1038/onc.2011.490

103.

Ye, X.-Q., Li, Q., Wang, G.-H., Sun, F.-F., Huang, G.-J., Bian, X.-W., … Qian, G.-S. (2011). Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. International Journal of Cancer, 129(4), 820–831. https://doi.org/10.1002/ijc.25944

104.

Yasuda, T., Ishimoto, T., & Baba, H. (2021). Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche. Regenerative Therapy, 17, 8–12. https://doi.org/10.1016/j.reth.2021.01.005CrossRefPubMedPubMedCentral

105.

Sriramkumar, S., Sood, R., Huntington, T. D., Ghobashi, A. H., Vuong, T. T., Metcalfe, T. X., … O’Hagan, H. M. (2022). Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. Journal of Translational Medicine, 20(1), 246. https://doi.org/10.1186/s12967-022-03447-y

106.

Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clément-Schatlo, V., … Stamenkovic, I. (2012). Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes & Development, 26(17), 1926–1944. https://doi.org/10.1101/gad.188292.112

107.

Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., … Heeschen, C. (2015). MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabolism, 22(4), 590–605. https://doi.org/10.1016/j.cmet.2015.08.015

108.

Vlashi, E., Lagadec, C., Vergnes, L., Matsutani, T., Masui, K., Poulou, M., … Pajonk, F. (2011). Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences, 108(38), 16062–16067. https://doi.org/10.1073/pnas.1106704108

109.

Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., … Li, J. J. (2022). Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nature Communications, 13(1), 1511. https://doi.org/10.1038/s41467-022-29137-3

110.

Zhu, Y., Lin, X., Zhou, X., Prochownik, E. V., Wang, F., & Li, Y. (2022). Posttranslational control of lipogenesis in the tumor microenvironment. Journal of Hematology & Oncology, 15(1), 120. https://doi.org/10.1186/s13045-022-01340-1CrossRef

111.

Ferguson, L. P., Diaz, E., & Reya, T. (2021). The role of the microenvironment and immune system in regulating stem cell fate in cancer. Trends in Cancer, 7(7), 624–634. https://doi.org/10.1016/j.trecan.2020.12.014CrossRefPubMedPubMedCentral

112.

Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences of the United States of America, 110(3), 972–977. https://doi.org/10.1073/pnas.1221055110CrossRefPubMed

113.

Johnson, D. E., O’Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews. Clinical Oncology, 15(4), 234–248. https://doi.org/10.1038/nrclinonc.2018.8CrossRefPubMedPubMedCentral

114.

Park, H.-B., Paik, D.-J., Jang, E., Hong, S., & Youn, J. (2004). Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. International Immunology, 16(8), 1203–1213. https://doi.org/10.1093/intimm/dxh123CrossRefPubMed

115.

Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013). Current status of interleukin-10 and regulatory T-cells in cancer. Current Opinion in Oncology, 25(6), 637–645. https://doi.org/10.1097/CCO.0000000000000006CrossRefPubMedPubMedCentral

116.

Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., … Hirano, T. (2004). IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. Journal of Immunology (Baltimore, Md.: 1950), 173(6), 3844–3854. https://doi.org/10.4049/jimmunol.173.6.3844

117.

Ozawa, Y., Yamamuro, S., Sano, E., Tatsuoka, J., Hanashima, Y., Yoshimura, S., … Yoshino, A. (2020). Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells. Biochemical and Biophysical Research Communications, 524(3), 723–729. https://doi.org/10.1016/j.bbrc.2020.01.148

118.

Ju, J.-M., Nam, G., Lee, Y.-K., Jung, M., Chang, H., Kim, W., … Choi, E. Y. (2021). IDO1 scavenges reactive oxygen species in myeloid-derived suppressor cells to prevent graft-versus-host disease. Proceedings of the National Academy of Sciences, 118(10), e2011170118. https://doi.org/10.1073/pnas.2011170118

119.

Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020). The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer, 122(1), 30–44. https://doi.org/10.1038/s41416-019-0664-6CrossRefPubMed

120.

Stone, T. W., & Williams, R. O. (2023). Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends in Pharmacological Sciences, 44(7), 442–456. https://doi.org/10.1016/j.tips.2023.04.006CrossRefPubMed

121.

Lužnik, Z., Anchouche, S., Dana, R., & Yin, J. (2020). Regulatory T cells in angiogenesis. Journal of Immunology (Baltimore, Md.: 1950), 205(10), 2557–2565. https://doi.org/10.4049/jimmunol.2000574

122.

Liu, C., Chikina, M., Deshpande, R., Menk, A. V., Wang, T., Tabib, T., … Vignali, D. A. A. (2019). Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ. Immunity, 51(2), 381–397.e6. https://doi.org/10.1016/j.immuni.2019.06.017

123.

Da-Veiga, M.-A., Coppieters, N., Lombard, A., Rogister, B., Neirinckx, V., & Piette, C. (2023). Comprehensive profiling of stem-like features in pediatric glioma cell cultures and their relation to the subventricular zone. Acta Neuropathologica Communications, 11(1), 96. https://doi.org/10.1186/s40478-023-01586-xCrossRefPubMedPubMedCentral

124.

Thirant, C., Bessette, B., Varlet, P., Puget, S., Cadusseau, J., Dos Reis Tavares, S., … Junier, M.-P. (2011). Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS ONE, 6(1), e16375. https://doi.org/10.1371/journal.pone.0016375

125.

De Wet, L., Williams, A., Gillard, M., Kregel, S., Lamperis, S., Gutgesell, L. C., … Vander Griend, D. J. (2022). SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene, 41(8), 1190–1202. https://doi.org/10.1038/s41388-021-02157-x

126.

Da-Veiga, M.-A., Rogister, B., Lombard, A., Neirinckx, V., & Piette, C. (2022). Glioma stem cells in pediatric high-grade gliomas: From current knowledge to future perspectives. Cancers, 14(9), 2296. https://doi.org/10.3390/cancers14092296CrossRefPubMedPubMedCentral

127.

Neradil, J., & Veselska, R. (2015). Nestin as a marker of cancer stem cells. Cancer Science, 106(7), 803–811. https://doi.org/10.1111/cas.12691CrossRefPubMedPubMedCentral

128.

Surowiec, R. K., Ferris, S. F., Apfelbaum, A., Espinoza, C., Mehta, R. K., Monchamp, K., … Galban, S. (2021). Transcriptomic analysis of diffuse intrinsic pontine glioma (DIPG) identifies a targetable ALDH-positive subset of highly tumorigenic cancer stem-like cells. Molecular Cancer Research, 19(2), 223–239. https://doi.org/10.1158/1541-7786.MCR-20-0464

129.

Murakami, T., Nakazawa, T., Natsume, A., Nishimura, F., Nakamura, M., Matsuda, R., … Nakase, H. (2018). Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells. Anticancer Research, 38(9), 5049–5056. https://doi.org/10.21873/anticanres.12824

130.

Khan, M., Arooj, S., & Wang, H. (2020). NK cell-based immune checkpoint inhibition. Frontiers in Immunology, 11, 167. https://doi.org/10.3389/fimmu.2020.00167CrossRefPubMedPubMedCentral

131.

Sönmez, C., Wölfer, J., Holling, M., Brokinkel, B., Stummer, W., Wiendl, H., … Grauer, O. M. (2022). Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. Scientific Reports, 12(1), 6769. https://doi.org/10.1038/s41598-022-10680-4

132.

Weiss, T., Schneider, H., Silginer, M., Steinle, A., Pruschy, M., Polić, B., … Roth, P. (2018). NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(4), 882–895. https://doi.org/10.1158/1078-0432.CCR-17-1766

133.

Pawlowski, K. D., Duffy, J. T., Tiwari, A., Zannikou, M., & Balyasnikova, I. V. (2023). Bi-specific killer cell engager enhances NK cell activity against interleukin-13 receptor alpha-2 positive gliomas. Cells, 12(13), 1716. https://doi.org/10.3390/cells12131716CrossRefPubMedPubMedCentral

134.

Datsi, A., & Sorg, R. V. (2021). Dendritic cell vaccination of glioblastoma: Road to success or dead end. Frontiers in Immunology, 12, 770390. https://doi.org/10.3389/fimmu.2021.770390CrossRefPubMedPubMedCentral

135.

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., … Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150. https://doi.org/10.1038/s41586-023-06063-y

136.

Catania, G., Rodella, G., Vanvarenberg, K., Préat, V., & Malfanti, A. (2023). Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials, 294, 122006. https://doi.org/10.1016/j.biomaterials.2023.122006CrossRefPubMed

137.

Segura-Collar, B., Hiller-Vallina, S., de Dios, O., Caamaño-Moreno, M., Mondejar-Ruescas, L., Sepulveda-Sanchez, J. M., & Gargini, R. (2023). Advanced immunotherapies for glioblastoma: Tumor neoantigen vaccines in combination with immunomodulators. Acta Neuropathologica Communications, 11(1), 79. https://doi.org/10.1186/s40478-023-01569-yCrossRefPubMedPubMedCentral

138.

Xun, Y., Yang, H., Kaminska, B., & You, H. (2021). Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. Journal of Hematology & Oncology, 14(1), 176. https://doi.org/10.1186/s13045-021-01191-2CrossRef

139.

Parker, S., McDowall, C., Sanchez-Perez, L., Osorio, C., Duncker, P. C., Briley, A., … Chandramohan, V. (2023). Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science Translational Medicine, 15(682), eabn5649. https://doi.org/10.1126/scitranslmed.abn5649

140.

Didenko, V. V., Ngo, H. N., Minchew, C., & Baskin, D. S. (2002). Apoptosis of T lymphocytes invading glioblastomas multiforme: A possible tumor defense mechanism. Journal of Neurosurgery, 96(3), 580–584. https://doi.org/10.3171/jns.2002.96.3.0580CrossRefPubMed

141.

Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., … Gargett, T. (2022). Characterising distinct migratory profiles of infiltrating T-cell subsets in human glioblastoma. Frontiers in Immunology, 13, 850226. https://doi.org/10.3389/fimmu.2022.850226

142.

Chen, D., Varanasi, S. K., Hara, T., Traina, K., Sun, M., McDonald, B., … Kaech, S. M. (2023). CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity, 56(9), 2086–2104.e8. https://doi.org/10.1016/j.immuni.2023.07.015

143.

Amoozgar, Z., Kloepper, J., Ren, J., Tay, R. E., Kazer, S. W., Kiner, E., … Jain, R. K. (2021). Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nature Communications, 12(1), 2582. https://doi.org/10.1038/s41467-021-22885-8

144.

Kesarwani, P., Prabhu, A., Kant, S., Kumar, P., Graham, S. F., Buelow, K. L., … Chinnaiyan, P. (2018). Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(15), 3632–3643. https://doi.org/10.1158/1078-0432.CCR-18-0041

145.

Ahluwalia, M. S., Reardon, D. A., Abad, A. P., Curry, W. T., Wong, E. T., Belal, A., … Fenstermaker, R. (2019). SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. Journal of Clinical Oncology, 37(15_suppl), 2016–2016. https://doi.org/10.1200/JCO.2019.37.15_suppl.2016

146.

Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., … Hutson, A. D. (2016). Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunology, Immunotherapy, 65(11), 1339–1352. https://doi.org/10.1007/s00262-016-1890-x

147.

Flores, C., Wildes, T., Dean, B. D., Moore, G., Drake, J., Abraham, R., … Mitchell, D. (2019). Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances, 5(11), eaav9879. https://doi.org/10.1126/sciadv.aav9879

148.

Choi, B. D., Kuan, C.-T., Cai, M., Archer, G. E., Mitchell, D. A., Gedeon, P. C., … Sampson, J. H. (2013). Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences, 110(1), 270–275. https://doi.org/10.1073/pnas.1219817110

149.

Choi, B. D., Yu, X., Castano, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., … Maus, M. V. (2019). CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 37(9), 1049–1058. https://doi.org/10.1038/s41587-019-0192-1

150.

O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., … Maus, M. V. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 9(399), eaaa0984. https://doi.org/10.1126/scitranslmed.aaa0984

151.

Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., … Mackall, C. L. (2018). Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nature Medicine, 24(5), 572–579. https://doi.org/10.1038/s41591-018-0006-x

152.

Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., … Mackall, C. L. (2019). CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clinical Cancer Research, 25(8), 2560–2574. https://doi.org/10.1158/1078-0432.CCR-18-0432

153.

Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K. J., & Rodriguez, A. (2020). CAR T cell therapy for pediatric brain tumors. Frontiers in Oncology, 10. Retrieved from https://www.frontiersin.org/journals/oncology/articles/https://doi.org/10.3389/fonc.2020.01582

154.

Sato, A., Sunayama, J., Okada, M., Watanabe, E., Seino, S., Shibuya, K., … Kitanaka, C. (2012). Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Translational Medicine, 1(11), 811–824. https://doi.org/10.5966/sctm.2012-0058

155.

Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., & Kitanaka, C. (2014). Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget, 6(2), 651–661.CrossRefPubMedCentral

156.

Zhao, H., Yan, C., Hu, Y., Mu, L., Liu, S., Huang, K., … Qin, J. (2020). Differentiated cancer cell-originated lactate promotes the self-renewal of cancer stem cells in patient-derived colorectal cancer organoids. Cancer Letters, 493, 236–244. https://doi.org/10.1016/j.canlet.2020.08.044

157.

Kim, S., & Singh, S. V. (2022). Monocarboxylate transporter 1 is a novel target for breast cancer stem like-cell inhibition by diallyl trisulfide. Molecular Carcinogenesis, 61(8), 752–763. https://doi.org/10.1002/mc.23415CrossRefPubMedPubMedCentral

158.

Longhitano, L., Vicario, N., Tibullo, D., Giallongo, C., Broggi, G., Caltabiano, R., … Li Volti, G. (2022). Lactate induces the expressions of MCT1 and HCAR1 to promote tumor growth and progression in glioblastoma. Frontiers in Oncology, 12, 871798. https://doi.org/10.3389/fonc.2022.871798

159.

Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., … Khasraw, M. (2021). Targeting immunometabolism in glioblastoma. Frontiers in Oncology, 11, 696402. https://doi.org/10.3389/fonc.2021.696402

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Glioblastoma stem cell metabolism and immunity

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer